Latest:
Dr Eng on the Implications of a Real-World Study in KRAS G12C–Mutated CRC
Cathy Eng, MD, FACP, FASCO, discusses the clinical significance of a real-world study of KRAS G12C mutations on treatment outcomes in mCRC.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Cathy Eng, MD, FACP, The University of Texas MD Anderson Cancer Center
Latest:
Second-Line Treatment of mCRC: Rechallenging Therapy
The role of molecular assays, including liquid biopsies, in providing information on resistance mechanisms in metastatic colorectal cancer and the impact of testing results on decisions for rechallenging with a previous therapy.
Cecile Pizot
Latest:
Cecile Pizot on Breast Cancer Mortality in Latin America and Asia
Cecile Pizot, biostatistician in epidemiology at the International Prevention Research Institute, discusses the changes in mortality rates in breast cancer around the world. In a study on 47 countries, 39 saw breast cancer mortality rates decline, but mortality rates were on the rise in Latin American and Asian countries.
Celestia Higano, MD
Latest:
Dr. Higano on the Effectiveness of PARP Inhibitors for Prostate Cancer
Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses the effectiveness of PARP inhibitors for patients with metastatic prostate cancer.
Celestia Higano, MD, FACP
Latest:
Dr. Higano on the Toxicity of Androgen Receptor Inhibitors in CRPC
Celestia Higano, MD, FACP, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, professor, Department of Medicine and Urology, University of Washington, Seattle Cancer Care Alliance, discusses the toxicity of androgen receptor inhibitors in castration-resistant prostate cancer.